Sinopharm Capital, the private equity fund started by China’s largest pharma, Sinopharm Group, co-led an $18 million B round in Virtual Incision, a Nebraska medical device company. Virtual Incision is developing a next-gen miniaturized robotically assisted surgical device (RASD) for minimally invasive abdominal surgeries, such as colon resection. Competing RASDs usually require large, open incisions for multi-quadrant abdominal operations. Virtual Incision will initially file for US approval of the device, but it plans to form a China JV to develop the device for China use.
Source: China Biotoday
